Verrica Pharmaceuticals (NASDAQ:VRCA) Price Target Raised to $14.00

Verrica Pharmaceuticals (NASDAQ:VRCAGet Free Report) had its target price upped by research analysts at HC Wainwright from $13.00 to $14.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 46.44% from the stock’s previous close.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price on shares of Verrica Pharmaceuticals in a research report on Wednesday, April 10th.

Check Out Our Latest Report on Verrica Pharmaceuticals

Verrica Pharmaceuticals Price Performance

Shares of Verrica Pharmaceuticals stock opened at $9.56 on Tuesday. The firm has a market capitalization of $405.54 million, a PE ratio of -6.55 and a beta of 1.82. The company has a current ratio of 4.55, a quick ratio of 4.49 and a debt-to-equity ratio of 2.22. Verrica Pharmaceuticals has a 12 month low of $2.86 and a 12 month high of $9.61. The business’s 50-day moving average price is $6.31 and its 200-day moving average price is $5.48.

Verrica Pharmaceuticals (NASDAQ:VRCAGet Free Report) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The business had revenue of $1.99 million for the quarter, compared to the consensus estimate of $1.10 million. Verrica Pharmaceuticals had a negative net margin of 1,307.47% and a negative return on equity of 119.46%. Sell-side analysts forecast that Verrica Pharmaceuticals will post -1.59 EPS for the current fiscal year.

Institutional Trading of Verrica Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of VRCA. FMR LLC raised its holdings in Verrica Pharmaceuticals by 29.4% during the 3rd quarter. FMR LLC now owns 1,504,716 shares of the company’s stock valued at $5,846,000 after buying an additional 341,584 shares during the last quarter. BML Capital Management LLC raised its stake in shares of Verrica Pharmaceuticals by 20.0% during the fourth quarter. BML Capital Management LLC now owns 180,000 shares of the company’s stock valued at $1,318,000 after acquiring an additional 30,000 shares during the last quarter. Jump Financial LLC purchased a new stake in shares of Verrica Pharmaceuticals during the third quarter worth about $71,000. Kovitz Investment Group Partners LLC grew its stake in shares of Verrica Pharmaceuticals by 44.3% in the third quarter. Kovitz Investment Group Partners LLC now owns 50,125 shares of the company’s stock worth $195,000 after purchasing an additional 15,400 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Verrica Pharmaceuticals by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,268,710 shares of the company’s stock valued at $7,511,000 after purchasing an additional 7,609 shares during the last quarter. Institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

(Get Free Report)

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.

Recommended Stories

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.